Premium
The use of cytokines, fusion proteins and antibodies to treat cutaneous T‐cell lymphoma
Author(s) -
Rook Alain H.,
McGinnis Karen S.,
Richardson Stephen K.,
Budgin Jeanne B.,
Wysocka Maria,
Benoit Bernice M.,
Hopkins Jacqueline M. J.,
Vittorio Carmela C.
Publication year - 2003
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/j.1396-0296.2003.01645.x
Subject(s) - medicine , lymphoma , immune system , immunology , antibody , cutaneous t cell lymphoma , interferon , fusion protein , cytokine , immunotherapy , mycosis fungoides , biology , biochemistry , gene , recombinant dna
It has long been known that certain immune augmenting therapeutics, particularly interferon alpha, can exert profound salutary effects on the clinical progress of patients with cutaneous T‐cell lymphoma. Emerging evidence that the host immune response may play an important role in the control of this disorder has led to the clinical application of other cytokines including interleukin‐12 and interferon gamma. In this review, the authors will summarize current knowledge regarding the use of cytokines, fusion proteins and antibodies for the treatment of cutaneous T‐cell lymphoma.